Rennova Health Postpones Special Meeting of Stockholders to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
276
Rennova Health Postpones Special Meeting of Stockholders to May 26, 2017

WEST PALM BEACH, FL --(Marketwired - May 18, 2017) - Rennova Health, Inc. ( NASDAQ : RNVA ) , ( NASDAQ : RNVAZ ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces the postponement of its Special Meeting of stockholders that was to have taken place on May 19, 2017. The postponement is necessary to achieve a quorum of shares represented at the meeting. The new date for the Special Meeting is May 26, 2017 at 11:00 a.m. Eastern time and it will take place at the offices of Shutts & Bowen LLP, 525 Okeechobee Boulevard, Suite 1100, West Palm Beach, FL 33401. The record date of April 21, 2017 remains unchanged.

The Special Meeting is for the following purposes:

  1. To approve, for the purpose of Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying Senior Secured Original Issue Discount Convertible Debentures and three series of Warrants issued by the Company pursuant to the terms of that certain Securities Purchase Agreement, dated as of March 15, 2017, and those certain Exchange Agreements, dated as of March 15, 2017, between the Company and the investors named therein, in an amount in excess of 19.99% of the Company's Common Stock outstanding before the issuance of such Senior Secured Original Issue Discount Convertible Debentures and Warrants;
  2. To authorize an adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1; and
  3. To transact such other business as may properly come before the Special Meeting or any adjournment or postponement thereof.

"Although the vast majority of votes cast to date have been in favor of the proposals, the number of shares cast is insufficient for a quorum and our proxy solicitation firm requires more time to solicit votes from our stockholders," commented Seamus Lagan, chief executive officer of Rennova Health.

Stockholders who have already voted do not need to recast their votes. Stockholders who have not yet voted are encouraged to do so.

Stockholders that own their shares in "street name" through a stock brokerage account or through a bank or nominee should consult the broker, bank or nominee about its procedures to vote the shares.

About Rennova Health, Inc. Rennova provides industry-leading diagnostics and supportive software solutions to healthcare providers, delivering an efficient, effective patient experience and superior clinical outcomes. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information, please visit www.rennovahealth.com .

Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company's most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

Contacts: Rennova Health Sebastien Sainsbury 561-666-9818 ssainsbury@rennovahealth.com Investors LHA Kim Golodetz 212-838-3777 Kgolodetz@lhai.com or Bruce Voss 310-691-7100 Bvoss@lhai.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voter Events by Valley Community Healthcare Aim to Empower

Updated Category News Views 16

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang

Updated Category News Views 25

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Continue Reading
Hyliion Class Action Deadline Nears for Investors

Updated Category News Views 24

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors

Updated Category News Views 22

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest

Updated Category News Views 14

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil

Updated Category News Views 19

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 20

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading

Top 5 Most Recently Viewed Articles

Wingderm USA Expands Its Footprint at 2025 Aesthetic Show

Updated Category News Views 187

Wingderm USA Takes Center Stage at The Aesthetic Show 2025 Wingderm®, an innovative leader in energy-based medical aesthetic technologies, made a significant impact at The Aesthetic Show (TAS) 2025. This event was a pivotal moment in strengthening Wingderm’s position within the U.S. medical aesthetic market. It was held at a renowned venue and brought together medical...

Continue Reading
INVO Bioscience's Strategic Cash Advance Enhances Financial Stability

Updated Category News Views 259

INVO Bioscience Secures Essential Funding INVO Bioscience, Inc. (NASDAQ:INVO), a prominent player in the medical device sector, has recently embarked on a significant financial maneuver to enhance its operational stability. By entering into a Merchant Cash Advance agreement, the company has obtained $265,000, aiming to bolster its working capital and support various...

Continue Reading
FibroGen Secures $160 Million from Sale to AstraZeneca

Updated Category News Views 120

FibroGen Triumphs with Strategic Sale of China Operations FibroGen, Inc. (NASDAQ: FGEN) is making waves in the biopharmaceutical industry with the recent announcement of its agreement to sell its China subsidiary to AstraZeneca for approximately $160 million. This important financial maneuver not only bolsters FibroGen's financial stability but also positions the company...

Continue Reading
Enzoic Teams Up with CIS CyberMarket for Cybersecurity

Updated Category News Views 76

Enzoic Partners with CIS CyberMarket to Strengthen Cybersecurity Enzoic is excited to announce a strategic partnership with CIS CyberMarket, a program designed to enhance the procurement of cybersecurity solutions for various U.S. government entities, nonprofits, and educational institutions. This collaboration aims to provide those organizations with effective,...

Continue Reading
Fosun's Strategic Sale of German Bank Gathers EUR670 Million

Updated Category News Views 589

Fosun International Completes Strategic Sale of HAL Fosun International Limited has successfully finalized the sale of 99.743% of shares in Hauck Aufhäuser Lampe Privatbank AG (HAL), bringing in EUR670 million. This strategic transaction is a significant part of Fosun's ongoing initiatives to optimize its portfolio and focus on core growth sectors. Transforming Private...

Continue Reading